An official website of the United States government

Publication Information

PubMed ID
Public Release Type
Journal
Publication Year
2010
Affiliation
Department of Pathology, University of Otago, Christchurch, New Zealand.
Authors
Barclay ML, Bentley RW, Cleynen I, Ferrante M, Gearry RB, Merriman TR, Roberts RL, Rutgeerts P, Vermeire S
Studies
Citation
Bentley RW, Cleynen I, Gearry RB, Barclay ML, Rutgeerts P, Merriman TR, Ferrante M, Roberts RL, Vermeire S. Evidence that glioma-associated oncogene homolog 1 is not a universal risk gene for inflammatory bowel disease in Caucasians. Genes Immun 2010 Sep;11(6):509-14. Epub 2010 May 6.

Abstract

The transcription factor glioma-associated oncogene homolog 1 (GLI1) has a central function in gastrointestinal tract development and homeostasis. A non-synonymous single-nucleotide polymorphism (SNP) (rs2228226; Q1100E) in GLI1, which impairs GLI1 function in vitro, has been proposed as a risk factor for inflammatory bowel disease (IBD). In this study, we assessed the cumulative evidence for association of GLI1 with IBD. New genotype data for rs2228226 from New Zealand (907 controls, 990 IBD patients) and Belgian Caucasian case-control data sets (312 controls, 1214 IBD patients) were combined with data from the National Institute of Diabetes and Digestive and Kidney Diseases and three previously studied Caucasian case-control data sets. Meta-analysis of rs2228226 did not detect any association with ulcerative colitis (UC) (P=0.09, odds ratio (OR)=1.07, 95% confidence interval (CI)=0.92-1.24), Crohn's disease (CD) (P=0.29, OR=1.06, 95% CI=0.93-1.21) or overall IBD (P=0.15, OR=1.05, 95% CI=0.92-1.19). Our analyses of rs2228226 suggest that GLI1 is not a significant risk factor for IBD in Caucasians.